Name of this trial: INAVO123
What type of cancer is this for? Breast Cancer
Who is this trial for? Patients with locally advanced or metastatic breast cancer.
What biomarkers are involved? PIK3CA-positive, ER+, HER2-
What is the National Clinical Trial #? NCT06790693
Brief summary of this trial: This is a blinded trial that consists of 2 potential arms to be randomized. Arm 1 is with Inavolisib (study drug) + Letrozole + palbociclib; VS Arm 2 Placebo + Letrozole + palbociclib.
Need to know: ER and/or PR positive, HER2 negative breast cancer patients after at least 2 years of standard endocrine therapy (i.e., tamoxifen, anastrozole, letrozole, exemestane, and/or oral selective estrogen receptor degrader) without disease progression during that treatment and disease-free interval of at least 1 year since completion of that treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial? Capitello-292
Phase of this trial? Phase 3
Who is this trial for? Men and Women with hormone positive, HER2 negative breast cancer that is locally advanced and inoperable.
What biomarkers are involved? None
Clinical Trial # NCT04862663
Brief Summary of Trial: This is a randomized 1:1 trial that is looking at new drug Capivasertib in combination with anti-hormone drug and a CDK4/6 inhibitor (oral drug), vs. anti-hormone drug plus CDK4/6 inhibitor. The study is looking for which works best.
Need to Know: Must have relapsed on or within 12 months of completing first line endocrine therapy (such as Tamoxifen, or another AI), maximum of 1 line of chemotherapy in advanced disease setting.
Where is this trial available? Cancer and Hematology Centers and other sites nationwide, please click on link for other locations,
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]